Helix BioPharma Corp. Announces Fiscal 20...(at a price of $2.87. Based on the Com...),Health

Based on the Company's currently planned expenditures and assuming no unanticipated expenses, the Company estimates its cash reserves will be sufficient to meet anticipated cash needs for working capital and capital expenditures for the next twelve months. The Company has no external sources of liquidity such as bank lines of credit. The Company will require future additional financing to carry out its business plan. The market for both debt and equity financings for companies such as Helix has always been challenging, and the global economic downturn and credit crisis have added further challenges. There can be no assurance that a financing, whether debt or equity, will be available on acceptable terms or at all.

The Company's consolidated fiscal 2009, 2008, and 2007 financial statements are summarized below.

    Consolidated Statements of Operations
    (thousand $, except for per share data)

                                              2009     2008     2007
                                              ----     ----     ----
    Revenue:
      Product revenue                        3,244    2,952    2,764
      License fees & royalties                 597      639      512
      Research and development contracts         -        -      148
                                                --       --      ---
                                             3,841    3,591    3,424

    Expenses:
      Cost of sales                          1,516    1,239    1,139
      Research and development              10,322    5,064    4,116
      Operating, general and admin           3,917    3,948    3,570
      Sales and marketing                      969      809      848
      Amortization of intangibles               12       16      159
      Amortization of capital assets           274      254      287
      Stock-based compensation               1,023       44       47
      Interest income               
'/>"/>
SOURCE  Helix BioPharma Corp.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 
Related medicine technology :

1. Helix BioPharma Provides Updates on Topical Interferon Alpha-2b and L-DOS47 Following Pre-IND Meetings With the U.S. FDA
2. J. Craig Venter, Ph.D. Receives Double Helix Medal from Cold Spring Harbor Laboratory
3. Helix Receives Approval to Open Sites in Germany for its Ongoing Clinical Trial With Topical Interferon Alpha-2b in Patients With Ano-Genital Warts
4. China Biopharmaceuticals Holdings, Inc. Shareholders Overwhelmingly Support Merger with NeoStem, Inc., a NYSE AMEX Listed Company Trading Under Symbol NBS
5. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentation of Zerenex (ferric citrate) for the Treatment of Hyperphosphatemia at the Upcoming American Society of Nephrology Renal Week Meeting in San Diego
6. NGM Biopharmaceuticals Appoints Dr. Arthur D. Levinson, Former Genentech CEO, to its Board of Directors
7. Laureate Pharma Announces Signing New Biopharmaceutical Development & Manufacturing Agreement
8. PDL BioPharma Completes October 1 Special Dividend Payment
9. DOR BioPharma Announces Private Equity Financing of $3.85 Million with its Partner Sigma-Tau and Other Institutional Investors
10. Keryx Biopharmaceuticals Phase 2 Data of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Renal Cell Cancer Selected for Oral Presentation at the Eighth International Kidney Cancer Symposium
11. DOR BioPharma Announces NIH Grant Award to Support Phase 1/2 Clinical Trial of DOR201 in Radiation Enteritis